37.73
price up icon1.42%   0.53
after-market After Hours: 38.15 0.42 +1.11%
loading
Agios Pharmaceuticals Inc stock is traded at $37.73, with a volume of 590.94K. It is up +1.42% in the last 24 hours and up +12.73% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$37.20
Open:
$37.54
24h Volume:
590.94K
Relative Volume:
1.00
Market Cap:
$2.19B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.3213
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
-4.87%
1M Performance:
+12.73%
6M Performance:
+11.86%
1Y Performance:
-20.45%
1-Day Range:
Value
$37.10
$38.12
1-Week Range:
Value
$37.09
$40.98
52-Week Range:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Name
Agios Pharmaceuticals Inc
Name
Phone
617-649-8600
Name
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Employee
488
Name
Twitter
@AgiosPharma
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
AGIO's Discussions on Twitter

Compare AGIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
37.73 2.15B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.87B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-24-25 Initiated H.C. Wainwright Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-10-24 Resumed Raymond James Outperform
Sep-27-24 Downgrade Leerink Partners Outperform → Market Perform
Feb-08-24 Initiated Cantor Fitzgerald Overweight
Feb-03-23 Initiated Piper Sandler Overweight
Nov-17-22 Upgrade Goldman Sell → Neutral
Jul-27-22 Upgrade SVB Leerink Mkt Perform → Outperform
Dec-03-21 Initiated BofA Securities Buy
Jul-30-21 Downgrade Goldman Neutral → Sell
Jul-01-21 Initiated Raymond James Mkt Perform
Jun-10-21 Initiated H.C. Wainwright Buy
Mar-01-21 Downgrade JP Morgan Overweight → Neutral
Mar-01-21 Upgrade SVB Leerink Mkt Perform → Outperform
Feb-26-21 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-22-20 Upgrade Barclays Equal Weight → Overweight
Mar-04-20 Initiated Barclays Equal Weight
Nov-26-19 Initiated Cantor Fitzgerald Overweight
Sep-23-19 Upgrade Guggenheim Neutral → Buy
May-23-19 Resumed Goldman Neutral
Feb-15-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-25-18 Initiated Leerink Partners Mkt Perform
May-23-18 Initiated Citigroup Buy
Apr-11-18 Reiterated Credit Suisse Outperform
Feb-15-18 Reiterated Needham Buy
Feb-15-18 Reiterated SunTrust Buy
Sep-15-17 Initiated RBC Capital Mkts Outperform
Aug-10-17 Reiterated Needham Buy
Aug-08-17 Reiterated SunTrust Buy
Aug-02-17 Upgrade Leerink Partners Mkt Perform → Outperform
Jun-26-17 Downgrade Janney Buy → Neutral
Jan-17-17 Upgrade Oppenheimer Perform → Outperform
Oct-24-16 Initiated Needham Buy
Jun-13-16 Upgrade JP Morgan Neutral → Overweight
May-18-16 Reiterated SunTrust Buy
View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

pulisher
02:47 AM

Intrahepatic Cholangiocarcinoma Market: Epidemiology, - openPR.com

02:47 AM
pulisher
03:54 AM

Live Scanner Shows Breakout on Agios Pharmaceuticals Inc.Technical Stock Breakout Predictions Signal Entry Points - metal.it

03:54 AM
pulisher
Jul 28, 2025

When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid wealth accumulation with smart picks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is Agios Pharmaceuticals Inc. company’s growth strategyMassive wealth growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Agios Pharmaceuticals Inc.High-yield capital appreciation - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Invest confidently with data-backed picks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

What drives Agios Pharmaceuticals Inc. stock priceRecord-breaking gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What risks could impact Agios Pharmaceuticals Inc. stock performanceFree Stock Market Trend Analysis - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Agios Pharmaceuticals Inc. stockSuperior risk-adjusted returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is Agios Pharmaceuticals Inc. a good long term investmentTremendous financial leverage - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Will Agios Pharmaceuticals Inc. stock split in the near futureJaw-dropping returns - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com

Jul 24, 2025
pulisher
Jul 23, 2025

BlackRock, Inc. Reduces Stake in Agios Pharmaceuticals Inc - GuruFocus

Jul 23, 2025
pulisher
Jul 23, 2025

Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO) - The Globe and Mail

Jul 23, 2025
pulisher
Jul 23, 2025

Agios Pharmaceuticals Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Lobbying Update: $20,000 of AGIOS PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals (AGIO): Analyst Maintains Buy Rating, Lowe - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals (AGIO): BofA Adjusts Price Target Amid Rev - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals price target lowered to $51 from $52 at BofA - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $51 - 富途牛牛

Jul 22, 2025
pulisher
Jul 21, 2025

Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN

Jul 21, 2025
pulisher
Jul 18, 2025

What makes Agios Pharmaceuticals Inc. stock attractive to long term investorsLow Risk Entry Points - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Is Agios Pharmaceuticals Inc. stock a growth or value playFree Daily Stock Market Updates - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Teacher Retirement System of Texas Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Jul 18, 2025
pulisher
Jul 15, 2025

why agios pharmaceuticals inc. stock attracts strong analyst attentionSafe High Return Entry Points - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Agios Pharmaceuticals Inc. stock price move sharplyDaily Gain Forecast - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET - The Manila Times

Jul 14, 2025
pulisher
Jul 14, 2025

Agios Pharmaceuticals to Host Conference Call on Second Quarter 2025 Financial Results and Business Highlights - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Rare Disease Leader Agios Sets Q2 Earnings Call: Key Updates Expected on PK Activation Therapies - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Public market insider buying at Extendicare (EXE) - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells $452,612.86 in Stock - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

FY2025 Earnings Estimate for AGIO Issued By Zacks Research - Defense World

Jul 14, 2025

Agios Pharmaceuticals Inc Stock (AGIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Scadden David
Director
Jul 10 '25
Sale
40.00
1,400
56,000
17,603
Gheuens Sarah
Chief Medical Officer
Jul 09 '25
Option Exercise
25.01
11,914
297,969
73,185
Gheuens Sarah
Chief Medical Officer
Jul 09 '25
Sale
37.99
11,914
452,601
61,271
$77.38
price up icon 10.28%
$37.27
price up icon 0.57%
$105.00
price up icon 3.19%
$26.74
price down icon 2.59%
$111.48
price down icon 1.16%
biotechnology ONC
$305.74
price up icon 3.81%
Cap:     |  Volume (24h):